Table 2:
Impact of COVID-19 on new subject enrollment in clinical trials
| Variables | Variables | YoYD* March 2020 Vs March 2019 | YoYD* April 2020 Vs April 2019 | YoYD* May 2020 Vs May 2019 |
|---|---|---|---|---|
| All countries, All Therapeutic areas | -65% | -79% | -74% | |
| Asia | China | -68% | -33% | -49% |
| India | -84% | -97% | -95% | |
| Japan | -44% | -69% | -72% | |
| South Korea | -61% | -42% | -54% | |
| Europe | France | -68% | -81% | -76% |
| Germany | -33% | -77% | -81% | |
| Italy | -53% | -49% | -65% | |
| Spain | -68% | -82% | -68% | |
| United States | -66% | -83% | -73% | |
| United Kingdom | -80% | -95% | -100% | |
| Therapeutic areas | Cardiovascular | -69% | -95% | -91% |
| CNS** | -68% | -76% | -75% | |
| Endocrine | -64% | -91% | -89% | |
| ID/ Anti infectives | -47% | -66% | -52% | |
| Oncology | -48% | -60% | -58% | |
| Respiratory | -34% | -86% | -81% | |
* YoYD = year-on-year difference ;
** CNS = central nervous system
Source: COVID-19 and Clinical Trials: The Medidata Perspective, Release 5.0 [5]